Savara (SVRA) Net Margin (2013 - 2020)

Savara (SVRA) posted quarterly Net Margin of 1374100.0% for Q4 2020, down 31696.94% quarter-over-quarter from 4321.48% in Q3 2020.

Savara (SVRA) Net Margin (2013 - 2020) Analysis & Trends

Savara (SVRA) has reported Net Margin for 5 consecutive years, with 1374100.0% the latest figure, recorded in Q4 2020.

In Q4 2020, Net Margin changed N/A year-over-year to 1374100.0%; the TTM figure through Mar 2022 stood at 4109700.0% (changed N/A YoY), while the FY2020 annual figure was 19305.45%, changed N/A from the prior year.
Net Margin fell to 1374100.0% in Q4 2020 per SVRA's latest filing, from 4321.48% in the prior quarter.
Across five years, Net Margin topped out at 13257.45% in Q2 2017 and bottomed at 1374100.0% in Q4 2020.
Historically, Net Margin has averaged 229876.45% across 3 years, with a median of 4819.25% in 2020.
On a YoY basis, Net Margin climbed as much as 1730977 bps in 2016 and fell as far as 1730977 bps in 2016.
Savara's Net Margin stood at 1508.75% in 2016, then jumped by 979 bps to 13257.45% in 2017, then sank by 10465 bps to 1374100.0% in 2020.
Business Quant data shows SVRA's Net Margin at 1374100.0% in Q4 2020, 4321.48% in Q3 2020, and 13257.45% in Q2 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.23%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	30.33%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	13.90%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	30.98%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	12.74%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-3.12%
10	Savara	1.11 Bn	1.11 Bn	-	-

Download Data